Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia

Journal of Diabetes and its Complications

Volumn 16, Issue 6, 2002, Pages 382-385

  Lee, I Te ^a,b   Sheu, Wayne Huey Herng ^a,b,c   Lin, Shih Yi ^a,d   Lee, Wen Jane ^a   Song, Yuh Min ^a   Liu, Hui Chen ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Coronary artery disease; hs CRP; LDL cholesterol; Statin

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; BLOOD; CLINICAL TRIAL; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TIME;

BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; SIMVASTATIN; TIME FACTORS;

EID: 0036860912     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(02)00184-8     Document Type: Article

References (29)

1. Albert, M. A., Danielson, E., Rifai, N., & Ridker, P. M., for the PRINCE Investigators (2001). Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. Journal of the American Medical Association, 286, 64-70.
2. Allain C.A., Poon L.S., Cban C.S., Richmond W., Fu P.C. Enzymatic determination of total serum cholesterol. Clinical Chemistry. 20:1974;470-475.
3. Arnalich F., Hernanz A., Lopez-Maderuelo D., Pena J.M., Camacho J., Madero R., Vazquez J.J., Montiel C. Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. Hormone and Metabolic Research. 32:2000;407-412.
4. Brisk P.S., Alerbs J.J. Precipitation methods for quantification of lipoprotein. Albers J.J., Segrest J.P. Methods in enzymology. 1986;78-100 Academic Press, London, UK.
5. Chen J.W., Gall M.A., Deckert M., Jensen J.S., Parving H.H. Increase serum concentration of von Willebrand factor in non-insulin-dependent diabetic patients with and without diabetic nephropathy. British Medical Journal. 311:1995;1405-1406.
6. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto E.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Journal of the American Medical Association. 279:1998;1615-1622.
7. Ford E.S. Body mass index, diabetes, and C-reactive protein among US adults. Diabetes Care. 22:1999;1971-1977.
8. Freeman D.J., Norrie J., Sattar N., Neely R.D., Cobbe S.M., Ford I., Isles C., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J., Shepherd J., Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 103:2001;357-362.
9. Friedwald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clinical Chemistry. 18:1972;499-502.
10. Gabbay K.H., Hasty K., Breslow J.L., Ellison R.C., Bunn H.F., Gallop P.M. Glycosylated haemoglobins and long term blood glucose control in diabetes mellitus. Journal of Clinical Endocrinology and Metabolism. 44:1977;859-864.
11. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. Journal of Clinical Investigation. 34:1955;1345-1353.
12. Hoffmeister A., Rothenbacher D., Bazner U., Frohlich M., Brenner H., Hombach V., Koenig W. Role of novel markers of inflammation in patients with stable coronary heart disease. American Journal of Cardiology. 87:2001;262-266.
13. Jager A., van Hinsbergh V.W., Kostense P.J., Emeis J.J., Yudkin J.S., Nijpels G., Dekker J.M., Heine R.J., Bouter L.M., Stehouwer C.D. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arteriosclerosis, Thrombosis, and Vascular Biology. 19:1999;3071-3078.
14. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 103:2001;1933-1935.
15. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. Journal of the American Medical Association. 241:1979;2035-2038.
16. Mendall M.A., Patel P., Ballam L., Strachan D., Northfield T.C. C reactive protein and its relation to cardiovascular risk factor: a population based cross sectional study. British Medical Journal. 312:1996;1061-1065.
17. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 30:1987;123-131.
18. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association. 286:2001;327-334.
19. Pyorala K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 20:1997;614-620.
20. Ridker P.M. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Annals of Internal Medicine. 130:1999;933-937.
21. Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto Jr., A. M., for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. (2001). Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. New England Journal of Medicine, 344, 1959-1965.
22. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with Cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:2001;1191-1193.
23. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
24. Ross R. Atherosclerosis - an inflammatory disease. New England Journal of Medicine. 340:1999;115-126.
25. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
26. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal. 321:2000;405-412.
27. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
28. Wahiefeld A.W. Triglyceride: determination after enzymatic hydrolysis. Bergmyer H.U. Method of enzymatic analysis. 1974;1831-1835 Academic Press, New York.
29. Yudkin J.S., Panahloo A., Stehouwer C., Emeis J.J., Bulmer K., Mohamed-Ali V., Denver A.E. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects. Diabetologia. 43:2000;1099-1106.